/Mckesson%20Corporation%20logo%20on%20building-by%20JHVEPhoto%20via%20iStock.jpg)
McKesson has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.
A Look Back at Healthcare Providers & Services Stocks’ Q1 Earnings: McKesson (NYSE:MCK) Vs The Rest Of The Pack
1 of Wall Street’s Favorite Stock with Impressive Fundamentals and 2 We Avoid
5 Insightful Analyst Questions From McKesson’s Q1 Earnings Call
1 S&P 500 Stock to Target This Week and 2 We Avoid
McKesson (NYSE:MCK) reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its oncology, multispecialty, pharmaceutical distribution and prescription...
MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives Continue
McKesson (NYSE:MCK) Misses Q1 CY2026 Revenue Estimates
McKesson Corporation (NYSE: MCK) has released its fiscal 2026 fourth quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results...